297 related articles for article (PubMed ID: 22842982)
1. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
[TBL] [Abstract][Full Text] [Related]
2. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
4. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection.
Wang B; Xu D; Yu X; Ding T; Rao H; Zhan Y; Zheng L; Li L
Ann Surg Oncol; 2011 Sep; 18(9):2585-93. PubMed ID: 21347781
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Li JF; Chu YW; Wang GM; Zhu TY; Rong RM; Hou J; Xu M
BJU Int; 2009 Feb; 103(3):399-405. PubMed ID: 19021626
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
7. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
8. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.
Demir L; Yigit S; Ellidokuz H; Erten C; Somali I; Kucukzeybek Y; Alacacioglu A; Cokmert S; Can A; Akyol M; Dirican A; Bayoglu V; Sari AA; Tarhan MO
Clin Exp Metastasis; 2013 Dec; 30(8):1047-62. PubMed ID: 23836289
[TBL] [Abstract][Full Text] [Related]
10. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
12. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.
Kim MH; Koo JS; Lee S
Oncology; 2013; 85(2):128-36. PubMed ID: 23948758
[TBL] [Abstract][Full Text] [Related]
13. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
[TBL] [Abstract][Full Text] [Related]
14. [Tumor-infiltrating FoxP3+ Tregs are associated with CD34 expression and prognosis of hepatocellular carcinoma].
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; DU Z
Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):25-9. PubMed ID: 22464702
[TBL] [Abstract][Full Text] [Related]
15. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.
Gupta S; Joshi K; Wig JD; Arora SK
Acta Oncol; 2007; 46(6):792-7. PubMed ID: 17653902
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus.
Zingg U; Montani M; Frey DM; Dirnhofer S; Esterman AJ; Went P; Oertli D
Eur J Surg Oncol; 2010 Jul; 36(7):670-7. PubMed ID: 20510571
[TBL] [Abstract][Full Text] [Related]
19. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
Oda N; Shimazu K; Naoi Y; Morimoto K; Shimomura A; Shimoda M; Kagara N; Maruyama N; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2012 Nov; 136(1):107-16. PubMed ID: 22986814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]